TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06217276

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Respiratory muscle fatigue protocol
Description: It will be performed using a powerbreath device at 60% of the maximum inspiratory pressure (MIP) amount obtained by measuring mouth pressure. The protocol includes 7 sets consisting of 2 minutes of inspiratory effort and 1 minute of rest. To further confirm the occurrence of fatigue, the patient will score fatigue using the modified Borg scale, and the score will be 5 or above11. During the application, heart rate, blood pressure and peripheral oxygen saturation will be monitored. The measurement will be performed once for each case.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Respiratory muscle fatigue protocol
Description: It will be performed using a powerbreath device at 60% of the maximum inspiratory pressure (MIP) amount obtained by measuring mouth pressure. The protocol includes 7 sets consisting of 2 minutes of inspiratory effort and 1 minute of rest. To further confirm the occurrence of fatigue, the patient will score fatigue using the modified Borg scale, and the score will be 5 or above11. During the application, heart rate, blood pressure and peripheral oxygen saturation will be monitored. The measurement will be performed once for each case.
Study: NCT05263505

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib 2 MG [Olumiant]
Description: Two tabs daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Target dose: 20mg weekly

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azathioprine
Description: Target dose: 2mg/kg daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate
Description: Target Dose: 1g twice daily
Study: NCT05905055

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BAT
Description: Dosage of BAT will be based per site's standard of care
Study: NCT06099015

Intervention type: DEVICE
Intervention: Cera™ Vascular Plug System
Description: The Cera™ Vascular Plug System is composed of Cera™ Vascular Plug and its accessory Introducer Kit. The Cera™ Vascular Plug is a self-expandable, cylindrical Ni-Ti wire mesh device.
Study: NCT06452394

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycyclin
Description: Belongs to the class of tetracyclines. It has bacteriostatic activity against a broad range of gram-positive and gram-negative bacteria. Its mechanism of action lies in the binding to the 30S ribosomal subunit
Study: NCT06359431

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Novel Smart Speculum
Description: The examiner will lubricate the intended speculum with a water-based lubricant then insert through the vagina. Immediately after the first speculum is inserted, and before the examiner attempts to expand the blades to visualize the cervix, the participant's comfort will be assessed using a modified version of the 0-10 Universal Pain Assessment Tool, which shows a series of faces ranging from happy face at 0, or no pain, to a crying face at 10, which represents worst pain possible. Her response will be recorded immediately.~Then the examiner will open the speculum adequately to visualise the cervix. At this point, the visual analogue scale will be given to the participant and told to indicate again the level of pain following manipulation of the speculum, using a scale of 0 (no pain) to 10 (the worst pain imaginable). Her response will be recorded immediately.
Study: NCT05421195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: corticosteroids therapy
Description: Oral corticosteroids

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Olfactory training
Description: repeat and deliberate sniffing of a set of odorants

Intervention type: OTHER
Group type: OTHER
Intervention: Olfactory training
Description: repeat and deliberate sniffing of a set of odorants
Study: NCT05046951

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Should I Screen website
Description: The Should I Screen educational website, developed by our consultant, Rafael Meza, PhD, is available at no cost, is written at an 8th grade reading level, requires 15 minutes to use, and undergoes regular updates (https://shouldiscreen.com). The goal is to increase lung screening awareness and to encourage a shared decision making visit with a provider. Sections of the website include the benefits (the reduced likelihood of dying from lung cancer) and harms (false alarms, overdiagnosis, more testing, and invasive procedures) of screening, causes of lung cancer, methods to reduce lung cancer risk, and the lung cancer risk calculator. Improvements in knowledge have been demonstrated with individuals eligible for screening.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Should I Screen print booklet
Description: The Should I Screen print-based education will be developed in Aim 1 and compared to the Should I Screen website in Aim 2. It will also be at the 8th grade level and will require 15 minutes to read. Although it will contain the same topics as the website, there is one inherent difference - it is not possible to include the interactive risk calculator in the print version. The print-based version will list all of the risk criteria that are included in the algorithm so that participants can see which ones apply to them. However, the risk calculator requires the computer algorithm to calculate a person's 6-year risk of developing lung cancer.
Study: NCT05531136

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Foot strengthening training
Description: a 12-weeks exercise program consisting of foot strengthening exercises prescribed for 5 daily sessions a week, of which 1 supervised, 20 minutes per session on top of the regular exercise therapy to prevent falling
Study: NCT05981716

Intervention type: OTHER
Intervention: No intervention
Description: This is an observational study. There is no intervention.
Study: NCT06387719

Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic resonance imaging
Description: * Basic sequence for ethical consideration: evaluation of casual findings.~* Structural MRI.~* Functional MRI (fMRI) in the Resting-state~* fMRI- task based. Presented in a computer screen on a magnetically compatible googles.
Study: NCT06001697

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Park prescription
Description: The park prescription given by the patients care-provider includes information about the health benefits of spending time in nature and detailed information about the parks in the neighboring area. As well as access to a web-based platform called ParkRx which includes information and details about events in the parks in the study area. Together with information about the frequency and duration of visits to the parks.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Regular health advice
Description: Regular health advice relating to lifestyle factors that can decrease the risk of chronic disease and/or reducing the burden of an existing chronic disease. Areas included are diet, physical activity, sleep, stress and medications.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Regular health advice
Description: Regular health advice relating to lifestyle factors that can decrease the risk of chronic disease and/or reducing the burden of an existing chronic disease. Areas included are diet, physical activity, sleep, stress and medications.
Study: NCT06359431

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Novel Smart Speculum
Description: The examiner will lubricate the intended speculum with a water-based lubricant then insert through the vagina. Immediately after the first speculum is inserted, and before the examiner attempts to expand the blades to visualize the cervix, the participant's comfort will be assessed using a modified version of the 0-10 Universal Pain Assessment Tool, which shows a series of faces ranging from happy face at 0, or no pain, to a crying face at 10, which represents worst pain possible. Her response will be recorded immediately.~Then the examiner will open the speculum adequately to visualise the cervix. At this point, the visual analogue scale will be given to the participant and told to indicate again the level of pain following manipulation of the speculum, using a scale of 0 (no pain) to 10 (the worst pain imaginable). Her response will be recorded immediately.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard speculum
Description: he examiner will lubricate the intended speculum with a water-based lubricant then insert through the vagina. Immediately after the first speculum is inserted, and before the examiner attempts to expand the blades to visualize the cervix, the participant's comfort will be assessed using a modified version of the 0-10 Universal Pain Assessment Tool, which shows a series of faces ranging from happy face at 0, or no pain, to a crying face at 10, which represents worst pain possible. Her response will be recorded immediately.~Then the examiner will open the speculum adequately to visualise the cervix. At this point, the visual analogue scale will be given to the participant and told to indicate again the level of pain following manipulation of the speculum, using a scale of 0 (no pain) to 10 (the worst pain imaginable). Her response will be recorded immediately.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard speculum
Description: he examiner will lubricate the intended speculum with a water-based lubricant then insert through the vagina. Immediately after the first speculum is inserted, and before the examiner attempts to expand the blades to visualize the cervix, the participant's comfort will be assessed using a modified version of the 0-10 Universal Pain Assessment Tool, which shows a series of faces ranging from happy face at 0, or no pain, to a crying face at 10, which represents worst pain possible. Her response will be recorded immediately.~Then the examiner will open the speculum adequately to visualise the cervix. At this point, the visual analogue scale will be given to the participant and told to indicate again the level of pain following manipulation of the speculum, using a scale of 0 (no pain) to 10 (the worst pain imaginable). Her response will be recorded immediately.
Study: NCT05266716

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Affect Methamphetamine Treatment Program
Description: Components of the treatment services include: contingency management (CM; monetary incentives for drug tests negative for stimulants), the digital behavioral therapy curriculum (based on CBT) delivered via the Affect app on smartphones, weekly one-on-one telemedicine (TM) with clinical personnel and group therapy, and referral to psychiatrist for medication support, as needed. The program incrementally builds skills and beliefs to develop personally meaningful strategies to combat cravings, using such techniques as regular app-promoted deep breathing exercises, daily exercise, and help in making and sticking to a relapse prevention plan. Counseling sessions are arranged via text sent by the Team Care advocate and also presented to the participant via the app as a reminder. Individual and group therapy sessions occur over Zoom, which is integrated into the app.~Contingency Management (CM). CM utilizes monetary incentives and rewards to promote behavior change.
Study: NCT06446258

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual therapy (myofascial release, soft tissue mobilization)
Description: Soft tissue mobilization will be performed by a team of experienced manual therapists.
Study: NCT05869916

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: psychological first aid
Description: The effect of psychological first aid on earthquake victims was measured using the resilience scale and the secondary traumatic stress scale.
Study: NCT05044273

Intervention type: DEVICE
Intervention: Synergy XD stent or Synergy Megatron™ Stent
Description: Percutaneous coronary intervention with Synergy XD stent or Synergy Megatron™ Stent
Study: NCT06645678

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elranatamab
Description: Elranatamab: Participants will receive SC administration of elranatamab QW or Q2W. The initial doses of elranatamab will be 12mg (C0D1), 32mg (C0D4), and 76mg (C0D8) and will serve as the 2 step-up priming regimen (Cycle 0). Then, 76mg weekly C1-C6 \> then 76mg bi-weekly from C7 for those achieving PR or better \> then 76mg q4weeks from C12 for those achieving CR or better response. If the participant subsequently begins to have an increase of disease burden not yet qualifying as PD according to IMWG criteria, dose intervals will return to weekly dosing.~premedication for Elranatamab: Acetaminophen 650mg (or paracetamol 500mg), Diphenhydramine 25mg (or equivalent), Dexamethasone 20mg (or equivalent).~In case of mezigdomide discontinuation due to reasons other than disease progression, elranatamab continuation +/- dexamethasone will be allowed until loss of response. The administration of elranatamab +/- dexamethasone will continue per study protocol schedule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mezigdomide
Description: The first day of study treatment dosing with mezigdomide is considered Day 1 of a cycle. (per recommended phase 2 dose, daily \[qd\], D1-21, q 4weeks). Capsules of mezigdomide will be taken by mouth with or without food.~In case of elranatamab discontinuation due to reasons other than disease progression, mezigdomide continuation +/- dexamethasone will be allowed until loss of response. The administration of mezigdomide will continue per study protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Administered at the dose of 20 mg/day from C1-3, then 10mg/day from C4-6 as a premedication for elranatamab.~(for those \>=75 yrs, with uncontrolled diabetes mellitus, history of intolerance: 10mg/day -\> 5mg/day)
Study: NCT05182476

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Luvadaxistat
Description: Oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Luvadaxistat
Description: Oral tablets
Study: NCT06520670

Intervention type: DIAGNOSTIC_TEST
Intervention: Urinary galectin-3 binding protein
Description: Investigate urinary galectin-3 binding protein (G3BP) as a biomarker for lupus nephritis and indicator for disease activity.

Intervention type: DIAGNOSTIC_TEST
Intervention: Urinary galectin-3 binding protein
Description: Investigate urinary galectin-3 binding protein (G3BP) as a biomarker for lupus nephritis and indicator for disease activity.

Intervention type: DIAGNOSTIC_TEST
Intervention: Urinary galectin-3 binding protein
Description: Investigate urinary galectin-3 binding protein (G3BP) as a biomarker for lupus nephritis and indicator for disease activity.
Study: NCT04990336

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Dachaihu decoction compound
Description: Dachaihu decoction compound includes Bupleurum, Rhubarb, Citrus aurantium, Scutellaria, Pinellia, White Peony, Jujube, Ginger.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rhubarb single medicine
Description: Rhubarb single medicine

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Regular therapies
Description: Regular therapies, such as fluid therapy, for acute pancreatitis

Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: Regular therapies
Description: Regular therapies, such as fluid therapy, for acute pancreatitis
Study: NCT05836012

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HIL-214
Description: 2 injections - given at 4 months and the second at 6 months of age.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 injections - given at 4 months and the second at 6 months of age.
Study: NCT05362916

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letermovir
Description: Participants in the treatment arm will take either 1 tablet of 480mg PO once daily or 2 tablets of 240mg PO once daily.
Study: NCT04990336

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Regular therapies
Description: Regular therapies, such as fluid therapy, for acute pancreatitis
Study: NCT05889572

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MaaT033
Description: MaaT033 is a Microbiome Ecosystem Therapy (MET), composed of allogeneic, full-ecosystem pooled biotherapeutic gut microbiota.
Study: NCT05221827

Intervention type: DIAGNOSTIC_TEST
Intervention: C2i Test
Description: The C2i-Test, a personalized molecular circulating tumor DNA (ctDNA) test, is an in vitro qualitative test that uses next generation sequencing (NGS)-based whole-genome sequencing (WGS) data for detecting molecular residual disease (MRD).
Study: NCT06484673

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosentan Dispersible Tablets
Description: 1 tablet of 32 mg Bosentan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bosentan Dispersible Tablets
Description: 1 tablet of 32 mg Bosentan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tracleer Tablet for Oral Suspension
Description: 1 tablet of 32 mg Bosentan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tracleer Tablet for Oral Suspension
Description: 1 tablet of 32 mg Bosentan
Study: NCT05664113

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplant (FMT)
Description: FMT Lower Delivery Microbiota Preparation, Dose: 250 mL of Microbiota Preparation Material and Route of administration: colonoscopy FMT Upper Delivery Microbiota Preparation, Dose: 60 mL of Microbiota Preparation Material and Route of administration: Naso-enteral tube

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplant (FMT)
Description: FMT Lower Delivery Microbiota Preparation, Dose: 250 mL of Microbiota Preparation Material and Route of administration: colonoscopy FMT Upper Delivery Microbiota Preparation, Dose: 60 mL of Microbiota Preparation Material and Route of administration: Naso-enteral tube
Study: NCT05578703

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fundic Ablation Sequentially in Combination with Endoscopic Sleeve Gastroplasty
Description: Fundic mucosal ablation followed by endoscopic sleeve gastroplasty in the treatment of adults with obesity

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fundic Mucosal Ablation with ERBE HybridAPC
Description: Fundic mucosal ablation utilizing approved ERBE HybridAPC
Study: NCT04677361

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: MILs™ in Combination with Pembrolizumab
Description: Efficacy and Safety of MILs™ in Combination with Pembrolizumab in Patients with NSCLC and SCLC
Study: NCT05578703

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Apollo ESG
Description: Using only Apollo ESG as approved per label
Study: NCT05916430

Intervention type: DIAGNOSTIC_TEST
Intervention: EarliPoint Investigational Device
Description: Infants will complete eye-tracking data collection at the age of 9 months on the EarliPoint Investigational Device. Eye-tracking video cameras will safely measure the movements of the child's eyes while they watch age-appropriate video scenes of other children playing together. Parents/Caregivers will complete screening forms and questionnaires about their baby's health and development. Parents/caregivers will complete surveys about their child's development. The surveys will be emailed, to be completed when the child is approximately 9, 12, 15, 18, 21, and 24 months old. If the child shows signs of developmental delay, the child will be asked to participate in a comprehensive developmental and diagnostic assessment.
Study: NCT06560619

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MENTOR
Description: Participants will attend a group-based, 8-week online program (a total of 40 hours) via Zoom videoconferencing. The program is split into three wellness sections (Mindfulness, Exercise, and Nutrition) and eight other sections (self-care skills, core values, outdoor time in nature, rest/relaxation, contribution to others, arts and leisure, relationships, and spiritual practice). Participants will access all assessment and intervention tools on any mobile device (phone, tablet, laptop, desktop) using a password-protected identification (ID) to log in via their devices. Health coaches can create intake flows to collect health data and track analytics. Participants can see their goals, upcoming intervention sessions, and activities through the study application (app). Features of the study app include goal setting, where participants record their goals, zoom videoconferencing links for online classes and coaching sessions, and the ability to share materials with participants.
Study: NCT04128774

Intervention type: DRUG
Intervention: Dexamethasone
Description: The case group receives dexamethasone based on the clinical indication.
Study: NCT05941897

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceralasertib
Description: Participants will receive ceralasertib oral tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Participants will receive durvalumab as an intravenous infusion
Study: NCT04246112

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Handwriting intervention
Description: children will practice handwriting 5 days p/week, 15-20 minutes p/day for 12 weeks using the movalyzer software program.
Study: NCT04387617

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Description: The product is a liquid formulation that will be prescribed at a dosage of 20 mg per day for a total of 3 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The product is a liquid formulation placebo that will be prescribed at an equivalent volume as active drug for 3 days
Study: NCT04831606

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: debridement
Description: Cleaning of the wound area

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: debridement
Description: Cleaning of the wound area

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Offloading
Description: Offloading performed with a standard brace to the calf (Optima Diab, from Molliter).
Study: NCT05548127

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARV-471
Description: Daily oral dosages of ARV-471 continuously, dose escalation/de-escalation in Phase 1b until the recommended phase 2 dose (RP2D) determined, cycles lasting 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Daily oral dosages of Abemaciclib continuously, cycles lasting 28 days